Skip to main content
. 2019 Feb 26;37(14):1169–1178. doi: 10.1200/JCO.18.00925

FIG 5.

FIG 5.

Intrinsic molecular subtype and efficacy of palbociclib (PAL). (A) Intrinsic subtype distribution of tumors in the PALOMA-3 trial. (B) Progression-free survival (PFS) in luminal A (LumA) and B (LumB) tumors. (C) Cyclin E1 (CCNE1) mRNA expression by intrinsic molecular subtype. BasalL, basal-like; FUL, fulvestrant; HER2E, human epidermal growth factor receptor 2–enriched; HR, hazard ratio; mPFS, median progression-free survival; NormL, normal-like; PBO, placebo.